Sigilon Therapeutics (NASDAQ:SGTX) Issues Quarterly Earnings Results

Sigilon Therapeutics (NASDAQ:SGTX – Get Rating) issued its quarterly earnings results on Thursday. The company reported ($0.43) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.10), MarketWatch Earnings reports.

SGTX opened at $0.75 on Friday. The business’s 50-day moving average price is $1.30 and its 200-day moving average price is $2.29. Sigilon Therapeutics has a 12 month low of $0.75 and a 12 month high of $14.15.

Separately, Zacks Investment Research raised Sigilon Therapeutics from a “hold” rating to a “buy” rating and set a $1.50 price target for the company in a research note on Thursday, March 17th. Two equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. According to data from MarketBeat, the company presently has a consensus rating of “Buy” and an average target price of $6.20.

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. Renaissance Technologies LLC increased its holdings in Sigilon Therapeutics by 131.8% during the 1st quarter. Renaissance Technologies LLC now owns 275,600 shares of the company’s stock valued at $405,000 after purchasing an additional 156,689 shares during the period. Bank of New York Mellon Corp increased its holdings in Sigilon Therapeutics by 46.3% during the 3rd quarter. Bank of New York Mellon Corp now owns 39,559 shares of the company’s stock valued at $223,000 after purchasing an additional 12,512 shares during the period. Wells Fargo & Company MN increased its holdings in Sigilon Therapeutics by 581.5% during the 2nd quarter. Wells Fargo & Company MN now owns 16,417 shares of the company’s stock valued at $176,000 after purchasing an additional 14,008 shares during the period. Citadel Advisors LLC increased its holdings in Sigilon Therapeutics by 57.9% during the 2nd quarter. Citadel Advisors LLC now owns 14,446 shares of the company’s stock valued at $155,000 after purchasing an additional 5,299 shares during the period. Finally, Goldman Sachs Group Inc. increased its holdings in Sigilon Therapeutics by 16.0% during the 4th quarter. Goldman Sachs Group Inc. now owns 55,526 shares of the company’s stock valued at $154,000 after purchasing an additional 7,666 shares during the period. Hedge funds and other institutional investors own 58.41% of the company’s stock.

About Sigilon Therapeutics (Get Rating)

Sigilon Therapeutics, Inc, a clinical stage biotechnology company, develops functional cures for patients with chronic diseases. Its lead product candidate is SIG-001, which is in Phase I/II clinical trial to prevent bleeding episodes in patients with moderate to severe Hemophilia A. The company is also developing SIG-005 to treat the non-neurological manifestations of mucopolysaccharidosis type 1; SIG-007 to provide continuous and prolonged release of functional enzyme at levels sufficient to produce clinical benefits and alleviate progression of the downstream aspects of Fabry disease; and SIG-002 to replace islet cells for the treatment of type 1 diabetes.

Featured Stories